Scalambra, L., Ruzzi, F., Pittino, O. M., Semprini, M. S., Cappello, C., Angelicola, S., . . . Lollini, P. Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. BMC.
Chicago Style (17th ed.) CitationScalambra, Laura, et al. Targeting PCSK9, Through an Innovative CVLP-based Vaccine, Enhanced the Therapeutic Activity of a CVLP-HER2 Vaccine in a Preclinical Model of HER2-positive Mammary Carcinoma. BMC.
MLA (9th ed.) CitationScalambra, Laura, et al. Targeting PCSK9, Through an Innovative CVLP-based Vaccine, Enhanced the Therapeutic Activity of a CVLP-HER2 Vaccine in a Preclinical Model of HER2-positive Mammary Carcinoma. BMC.
Warning: These citations may not always be 100% accurate.